Physician profile
Paul M Keller
NPI 1689677817
$3,448,801.96
in general payments reported to CMS, 2019-2025
6 companies · $456K in 2025
The $456K reported for 2025 was more than what 99% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545K · 2020: $449K · 2021: $481K · 2022: $485K · 2023: $520K · 2024: $512K · 2025: $456K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.4M · Consulting Fee: $67K · Travel and Lodging: $7,195 · Food and Beverage: $1,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,412,089.95 |
| Consulting Fee | $67,277.80 |
| Travel and Lodging | $7,194.80 |
| Food and Beverage | $1,569.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $3,398,653.15 | 2019-2025 | Firebird, Physio-Stim, Miscellaneous |
| Seaspine Orthopedics Corporation | $28,346.53 | 2019-2022 | |
| Curiteva, INC. | $21,681.50 | 2021-2025 | |
| Zavation Medical Products, LLC | $85.33 | 2019 | |
| Smith+Nephew, INC. | $18.20 | 2023 | Renasys Go V2 Home, Pico |
| Organogenesis INC. | $17.25 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.